Computational studies of influenza a virus at three important targets: Hemagglutinin, neuraminidase and M2 protein

Current Pharmaceutical Design

Volumn 17, Issue 17, 2011, Pages 1720-1739

  Rungrotmongkol, Thanyada ^a   Yotmanee, Pathumwadee ^a   Nunthaboot, Nadtanet ^b   Hannongbua, Supot ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

Author keywords

Avian influenza H5N1 virus; Computer aided drug design; Hemagglutinin; M2 channel; Neuraminidase; Pandemic influenza H1N1 virus; Theoretical calculations

Indexed keywords

A 315675; AMANTADINE; ANTIVIRUS AGENT; HEMAGGLUTININ; INAVIR; LANINAMIVIR; OSELTAMIVIR; OSELTAMIVIR PHOSPHONATE; OTV 2; PERAMIVIR; PERAMIVIR PHOSPHONATE; PROTEIN M2; RAPIACTA; RIMANTADINE; SIALIDASE; UNCLASSIFIED DRUG; ZANAMIVIR; ZANAMIVIR PHOSPHONATE;

BINDING AFFINITY; CATALYSIS; DRUG BINDING; DRUG STRUCTURE; DRUG TARGETING; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; LIFE CYCLE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTON TRANSPORT; REVIEW; VIRUS LIFE CYCLE; VIRUS RESISTANCE; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; COMPUTATIONAL BIOLOGY; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; NEURAMINIDASE; VIRAL MATRIX PROTEINS;

EID: 79960320028     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796355083     Document Type: Review

References (150)

1. Gong J, Fang H, Li M, et al. Potential targets and their relevant inhibitors in anti-influenza fields. Curr Med Chem 2009; 16: 3716-3739.
2. Prakash S. Swine flu diagnosis and treatment edn First. Delhi: Biotech Books; 2009.
3. Jiang S, Li R, Du L, Liu S. Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell 2010; 4: 342-354.
4. Bewley CA. Illuminating the switch in influenza viruses. Nat Biotechnol 2008; 26: 60-62.
5. Taubenberger JK. Influenza hemagglutinin attachment to target cells: 'birds do it, we do it'. Future Virol 2006; 1: 415-418.
6. Fouchier R, Kuiken T, Rimmelzwaan G, Osterhaus A. Global task force for influenza. Nature 2005; 435: 419-420.
7. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 2006; 312: 404-410.
8. Krug RM, Aramini JM. Emerging antiviral targets for influenza A virus. Trends Pharmacol Sci 2009; 30: 269-277.
9. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69: 531-569.
10. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459: 931-939.
11. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010; 285: 28403-28409.
12. Ekici ÖD, Paetzel M, Dalbey RE. Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad configuration. Protein Sci 2008; 17: 2023-2037.
13. Hedstrom L. Serine protease mechanism and specificity. Chem Rev 2002; 102: 4501-4524.
14. Ishida T, Kato S. Theoretical perspectives on the reaction mechanism of serine proteases: the reaction free energy profiles of the acylation process. J Am Chem Soc 2003; 125: 12035-12048.
15. Ishida T, Kato S. Role of Asp102 in the catalytic relay system of serine proteases: a theoretical study. J Am Chem Soc 2004; 126: 7111-7118.
16. Decha P, Rungrotmongkol T, Intharathep P, et al. Source of high pathogenicity of an avian influenza virus H5N1: why H5 is better cleaved by furin. Biophys J 2008; 95: 128-134.
17. Rungrotmongkol T, Decha P, Sompornpisut P, et al. Combined QM/MM mechanistic study of the acylation process in furin complexed with the H5N1 avian influenza virus hemagglutininχs cleavage site. Proteins 2009; 76: 62-71.
18. Li M, Wang B. Computational studies of H5N1 hemagglutinin binding with SA-alpha-2,3-Gal and SA-alpha-2, 6-Gal. Biochem Biophys Res Commun 2006; 347: 662-668.
19. Iwata T, Fukuzawa K, Nakajima K, et al. Theoretical analysis of binding specificity of influenza viral hemagglutinin to avian and human receptors based on the fragment molecular orbital method. Comput Biol Chem 2008; 32: 198-211.
20. Xu D, Newhouse EI, Amaro RE, et al. Distinct glycan topology for avian and human sialopentasaccharide receptor analogues upon binding different hemagglutinins: a molecular dynamics perspective. J Mol Biol 2009; 387: 465-491.
21. Newhouse EI, Xu D, Markwick PRL, et al. Mechanism of glycan receptor recognition and specificity switch for avian, swine, and human adapted influenza virus hemagglutinins: a molecular dynamics perspective. J Am Chem Soc 2009; 131: 17430-17442.
22. Matrosovich M, Tuzikov A, Bovin N, et al. Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals. J Virol 2000; 74: 8502-8512.
23. Glaser L, Stevens J, Zamarin D, et al. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol 2005; 79: 11533-11536.
24. Sawada T, Hashimoto T, Nakano H, Suzuki T, Ishida H, Kiso M. Why does avian influenza A virus hemagglutinin bind to avian receptor stronger than to human receptor? Ab initio fragment molecular orbital studies. Biochem Biophys Res Commun 2006; 351: 40-43.
25. Sawada T, Hashimoto T, Tokiwa H, et al. Ab initio fragment molecular orbital studies of influenza virus hemagglutinin-sialosaccharide complexes toward chemical clarification about the virus host range determination. Glycoconj J 2008; 25: 805-815.
26. Sawada T, Hashimoto T, Tokiwa H, et al. Ab initio base fragment molecular orbital studies of influenza viral hemagglutinin HA1 full-domains in complex with sialoside receptors. J Mol Genet Med 2008; 3: 133-142.
27. Sawada T, Fedorov DG, Kitaura K. Role of the key mutation in the selective binding of avian and human influenza hemagglutinin to sialosides revealed by quantum-mechanical calculations. J Am Chem Soc 2010; 132: 16862-16872.
28. Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol 2007; 81: 9950-9955.
29. Das P, Li J, Royyuru AK, Zhou R. Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity. J Comput Chem 2009; 30: 1654-1663.
30. Nunthaboot N, Rungrotmongkol T, Malaisree M, et al. Molecular insights into human receptor binding to 2009 H1N1influenza A hemagglutinin. Monatsh Chem 2010; 141: 801-807.
31. Nunthaboot N, Rungrotmongkol T, Malaisree M, et al. Evolution of human receptor binding affinity of H1N1 hemagglutinins from 1918 to 2009 pandemic influenza A virus. J Chem Inf Model 2010; 50: 1410-1417.
32. de Vries RP, de Vries E, Moore KS, Rigter A, Rottier PJM, de Haan CAM. Only two residues are responsible for the dramatic difference in receptor binding between swine and new pandemic H1 hemagglutinin. J Biol Chem 2011; 286: 5868-5875.
33. Lee AN, Hartono YD, Sun T, et al. Molecular dynamics studies of human receptor molecule in hemagglutinin of 1918 and 2009 H1N1 influenza viruses. J Mol Model 2010. DOI: 10.1007/s00894-010-0867-5.
34. Malaisree M, Rungrotmongkol T, Nunthaboot N, et al. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Amino Acids 2009; 37: 725-732.
35. Rungrotmongkol T, Intharathep P, Malaisree M, et al. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 2009; 385: 390-394.
36. Rungrotmongkol T, Malaisree M, Nunthaboot N, Sompornpisut P, Hannongbua S. Molecular prediction of oseltamivir efficiency against probable influenza A (H1N1-2009) mutants: molecular modeling approach. Amino Acids 2010; 39: 393-398.
37. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 2010; 54: 1834-1841.
38. Wang B, Dwyer DE, Blyth CC, et al. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections. Antiviral Res 2010; 87: 16-21.
39. Wang NX, Zheng JJ. Computational studies of H5N1 influenza virus resistance to oseltamivir. Protein Sci 2009; 18: 707-715.
40. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol 2007; 81: 12418-12426.
41. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA 2006; 295: 891-894.
42. Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM, Kuntz ID. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993; 32: 2967-2978.
43. Russell RJ, Kerry PS, Stevens DJ, et al. Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci USA 2008; 105: 17736-17741.
44. Tang G, Qiu Z, Lin X, et al. Discovery of novel 1-phenylcycloalkane carbamides as potent and selective influenza fusion inhibitors. Bioorg Med Chem 2010; 20: 3507-3510.
45. Vanderlinden E, Gökta- F, Cesur Z, et al. Novel inhibitors of influenza virus fusion: structure-activity relationship and interaction with the viral hemagglutinin. J Virol 2010; 84: 4277-4288.
46. Rossignol JF, Frazia SL, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem 2009; 284: 29798-29808.
47. Russell RJ, Haire LF, Stevens DJ, et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45-49.
48. Li Q, Qi J, Zhang W, et al. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 2010; 17: 1266-1268.
49. Raab M, Tvaroška I. The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling. J Mol Model 2010; DOI: 10.1007/s00894-010-0852-z.
50. Kobasa D, Kodihalli S, Luo M, et al. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. J Virol 1999; 73: 6743-6751.
51. Fran de Barros Jr J, Sales Alviano D, da Silva MH, et al. Characterization of sialidase from an influenza A (H3N2) virus strain: kinetic parameters and substrate specificity. Intervirology 2003; 46: 199-206.
52. Mochalova LV, Korchagina EY, Kurova VS, Shtyria JA, Gambaryan AS, Bovin NV. Fluorescent assay for studying the substrate specificity of neuraminidase. Anal Biochem 2005; 341: 190-193.
53. Aruksakunwong O, Malaisree M, Decha P, et al. On the lower susceptibility of oseltamivir to influenza neuraminidase subtype N1 than those in N2 and N9. Biophys J 2007; 92: 798-807.
54. Malaisree M, Rungrotmongkol T, Decha P, Intharathep P, Aruksakunwong O, Hannongbua S. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Proteins 2008; 71: 1908-1918.
55. Lawrenz M, Baron R, McCammon JA. Independent-trajectories thermodynamic-integration free-energy changes for biomolecular systems: determinants of H5N1 avian influenza virus neuraminidase inhibition by peramivir. J Chem Theory Comput 2009; 5: 1106-1116.
56. Lawrenz M, Wereszczynski J, Amaro R, Walker R, Roitberg A, McCammon JA. Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy. Proteins 2010; 78: 2523-2532.
57. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992; 14: 327-332.
58. Shie JJ, Fang JM, Wang SY, et al. Synthesis of Tamiflu and its phosphonate congeners possessing potent anti-influenza activity. J Am Chem Soc 2007; 129: 11892-11893.
59. Udommaneethanakit T, Rungrotmongkol T, Bren U, Frecer V, Stanislav M. Dynamic behavior of avian influenza a virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues. J Chem Inf Model 2009; 49: 2323-2332.
60. Wang P, Zhang JZH. Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase. J Phys Chem B 2010; 114: 12958-12964.
61. Park JW, Jo WH. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Eur J Med Chem 2010; 45: 536-541.
62. Le L, Lee E, Schulten K, Truong TN. Molecular modeling of swineinfluenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. PLoS curr 2009; doi: 10.1371/currents.RRN1015.
63. Rungrotmongkol T, Udommaneethanakit T, Malaisree M, et al. How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? Biophys Chem 2009; 145: 29-36.
64. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54: 79-88.
65. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother 2005; 49: 4075-4084.
66. Abed Y, Nehme B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 2008; 77: 163-166.
67. Ives JAL, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307-317.
68. de Jong MD, Thanh TT, Khanh TH, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2000, 353: 2667-2672.
69. Earhart KC, Elsayed NM, Saad MD, et al. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. J Infect Public Heath 2009; 2: 74-80.
70. Hurt AC, Holien JK, Parker MW, Barr IG. Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009; 69: 2523-2531
71. Kawai N, Ikematsu H, Tanaka O, et al. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons. J Infect Chemother 2010; DOI: 10.1007/s10156-010-0179-9.
72. Park JW, Jo WH. Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir. J Chem Inf Model 2009; 49: 2735-2741.
73. McKimm-Breschkin J, Sahasrabudhe A, Blick T, McDonald M. Mechanisms of resistance of influenza virus to neuraminidase inhibitors. International Congress Series 2001; 1219: 855-861.
74. Moscona A: Oseltamivir resistance--disabling Our Influenza Defenses. N Engl J Med. 2005; 353: 2633-2636.
75. von Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov 2007; 6: 967-974.
76. Pan D, Sun H, Bai C, Shen Y, Jin N, Liu H, Yao X. Prediction of zanamivir efficiency over the possible 2009 influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations. J Mol Model 2010; DOI: 10.1007/s00894-010-0929-8
77. Amaro RE, Minh DDL, Cheng LS, et al. Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design. J Am Chem Soc 2007; 129: 7764-7765
78. Du QS, Wang SQ, Chou KC. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem Biophys Res Commun 2007; 362: 525-531.
79. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J Med Chem 2008; 51: 3878-3894.
80. Rungrotmongkol T, Frecer V, De-Eknamkul W, Hannongbua S, Miertus S. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Antiviral Res 2009; 82: 51-58.
81. Rungrotmongkol T, Udommaneethanakit T, Frecer V, Miertus S. Combinatorial design of avian influenza neuraminidase inhibitors containing pyrrolidine core with a reduced susceptibility to viral drug resistance. Comb Chem High Throughput Screen. 2010; 13: 268-277.
82. Pinto LH, Dieckmann GR, Gandhi CS, et al. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc Natl Acad Sci USA 1997; 94: 11301-11306.
83. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-624.
84. Gandhi CS, Shuck K, Lear JD, et al. Cu(II) inhibition of the proton translocation machinery of the influenza A virus M2 protein. J Biol Chem 1999; 274: 5474-5482.
85. Kukol A, Adams PD, Rice LM, Brunger AT, Arkin IT. Experimentally based orientational refinement of membrane protein models: a structure for the influenza A M2 H+ channel. J Mol Biol 1999; 286: 951-962.
86. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008; 451: U591-U512.
87. Kovacs FA, Denny JK, Song Z, Quine JR, Cross TA. Helix tilt of the M2 transmembrane peptide from influenza A virus: an intrinsic property. J Mol Biol 2000; 295: 117-125.
88. Wang JF, Kim S, Kovacs F, Cross TA. Structure of the transmembrane region of the M2 protein H+ channel. Protein Sci 2001; 10: 2241-2250.
89. Tian CL, Gao PF, Pinto LH, Lamb RA, Cross TA. Initial structural and dynamic characterization of the M2 protein transmembrane and amphipathic helices in lipid bilayers. Protein Sci 2003; 12: 2597-2605.
90. Stouffer AL, Acharya R, Salom D, et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008; 451: 596-U513.
91. Nishimura K, Kim SG, Zhang L, Cross TA. The closed state of a H+ channel helical bundle combining precise orientational and distance restraints from solid state NMR-1. Biochemistry 2002; 41: 13170-13177.
92. Hu J, Asbury T, Achuthan S, et al. Backbone structure of the amantadine-blocked trans-membrane domain M2 proton channel from influenza A virus. Biophys. J. 2007; 92: 4335-4343.
93. Tobler K, Kelly ML, Pinto LH, Lamb RA. Effect of cytoplasmic tail truncations on the activity of the M2 ion channel of influenza A virus. J Virol 1999; 73: 9695-9701.
94. Acharya R, Carnevale V, Fiorin G, et al. Structure and mechanism of proton transport through the transmembrane tetrameric M2 protein bundle of the influenza A virus. Proc Natl Acad Sci USA 2010; 107: 15075-15080.
95. Astrahan P, Kass I, Cooper MA, Arkin IT. A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins 2004; 55: 251-257.
96. Kass I, Arkin IT. How pH opens a H+ channel: the gating mechanism of influenza a M2. Structure 2005; 13: 1789-1798.
97. Chen HN, Wu YJ, Voth GA. Proton transport behavior through the influenza a M2 channel: insights from molecular simulation. Biophys J 2007; 93: 3470-3479.
98. Khurana E, Dal Peraro M, DeVane R, Vemparala S, DeGrado WF, Klein ML. Molecular dynamics calculations suggest a conduction mechanism for the M2 proton channel from influenza A virus. Proc Natl Acad Sci USA 2009; 106: 1069-1074.
99. Leonov H, Arkin IT. Structure and dynamics of the influenza A M2 channel: a comparison of three structures. J Mol Model 2009; 15: 1317-1328.
100. Holsinger LJ, Alams R. Influenza virus M2 integral membrane protein is a homotetramer Stabilized by formation of disulfide bonds. Virology 1991; 183: 32-43.
101. Paterson RG, Takeda M, Ohigashi Y, Pinto LH, Lamb RA. Influenza B virus BM2 protein is an oligomeric integral membrane protein expressed at the cell surface. Virology 2003; 306: 7-17.
102. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4: 3021-3024.
103. Helenius A. Unpacking the incoming influenza virus Cell. Cell. 1992; 69: 577-578.
104. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69: 517-528.
105. Martin K, Helenius A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 1991; 67: 117-130.
106. Lin T-I, Schroeder C. Definitive assignment of proton selectivity and attoampere unitary current to the M2 ion channel protein of influenza A virus. J Virol 2001; 75: 3647-3656.
107. Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci USA 2009; 106: 7379-7384.
108. Cady SD, Schmidt-Rohr K, Wang J, Soto CS, Degrado WF, Hong M. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010; 463: 689-U127.
109. Tang YJ, Zaitseva F, Lamb RA, Pinto LH. The gate of the influenza virus M-2 proton channel is formed by a single tryptophan residue. J Biol Chem 2002; 277: 39880-39886.
110. Yi M, Cross TA, Zhou HX. A secondary gate as a mechanism for inhibition of the M2 proton channel by amantadine. J Phys Chem B 2008; 112: 7977-7979.
111. Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67: 5585-5594.
112. Czabotar PE, Martin SR, Hay AJ. Studies of structural changes in the M2 proton channel of influenza A virus by tryptophan fluorescence. Virus Res 2004; 99: 57-61.
113. Hu J, Fu RQ, Cross TA. The chemical and dynamical influence of the anti-viral drug amantadine on the M2 proton channel transmembrane domain. Biophys J 2007; 93: 276-283.
114. Hu J, Fu R, Nishimura K, et al. Histidines, heart of the hydrogen ion channel from influenza A virus: toward an understanding of conductance and proton selectivity. Proc Natl Acad Sci USA 2006; 103: 6865-6870.
115. Sharma M, Yi MG, Dong H, et al. Insight into the mechanism of the influenza a proton channel from a structure in a lipid bilayer. Science 2010; 330: 509-512.
116. Intharathep P, Laohpongspaisan C, Rungrotmongkol T, et al. How amantadine and rimantadine inhibit proton transport in the M2 protein channel. J Mol Graph Model 2008; 27: 342-348.
117. McCown MF, Pekosz A. Distinct domains of the influenza A virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006, 80: 8178-8189.
118. Chen BJ, Leser GP, Jackson D, Lamb RA. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J Virol 2008; 82: 10059-10070.
119. Venkataraman P, Lamb RA, Pinto LH. Chemical rescue of histidine selectivity filter mutants of the M2 ion channel of influenza A virus. J Biol Chem 2005; 280: 21463-21472.
120. Balannik V, Carnevale V, Fiorin G, et al. Functional studies and modeling of pore-lining residue mutants of the influenza A virus M2 ion channel. Biochemistry 2010; 49: 696-708.
121. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994; 68: 1551-1563.
122. Mould JA, Drury JE, Frings SM, et al. Permeation and activation of the M-2 ion channel of influenza A virus. J Biol Chem 2000; 275: 31038-31050.
123. Chizhmakov IV, Geraghty FM, Ogden DC, Hayhurst A, Antoniou M, Hay AJ. Selective proton permeability and pH regulation of the influenza virus M2 channel expressed in mouse erythroleukaemia cells. J Physiol 1996; 494: 329-336.
124. Shimbo K, Brassard DL, Lamb RA, Pinto LH. Ion selectivity and activation of the M2 ion channel of influenza virus. Biophys J 1996; 70: 1335-1346.
125. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 1992; 190: 485-489.
126. Phongphanphanee S, Rungrotmongkol T, Yoshida N, Hannongbua S, Hirata F. Proton transport through the influenza A M2 channel: three-dimensional reference interaction site model study. J Am Chem Soc 2010; 132: 9782-9788.
127. Sansom MSP, Kerr ID, Smith GR, Son HS. The influenza A virus M2 channel: a molecular modeling and simulation study. Virology 1997; 233: 163-173.
128. Agmon N. The Grotthuss mechanism. Chem Phys Lett 1995; 244: 456-462.
129. Krause J. Proline conformations in linear peptides. Structure determination of the methyl ester of N-benzyloxycarbonyl-L-prolyl-D-alanine (N-Z-L-Pro-D-Ala-OMe). Acta Crystallogr C 1991, 47: 1508-1512.
130. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (Amantadine). Science 1964; 144: 862-863.
131. Wang C, Lamb RA, Pinto LH. Direct measurement of the influenza A virus M2 protein ion channel activity in mammalian cells. Virology 1994; 205: 133-140.
132. Duff KC, Gilchrist PJ, Saxena AM, Bradshaw JP. Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel. Virology 1994; 202: 287-293.
133. Intharathep P, Rungrotmongkol T, Decha P, et al. Evaluating how rimantadines control the proton gating of the influenza A M2-proton port via allosteric binding outside of the M2-channel: MD simulations. J Enzyme Inhib Med Chem 2011; 26: 162-168.
134. Jefferson T, Demicheli V, Pietrantonj CD, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006; 19: CD001169.
135. Deyde VM, Xu XY, Bright RA, et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196: 249-257.
136. Suzuki H, Saito R, Masuda H, Oshitani H, Sato M, Sato I. Emergence of amantadine-resistant influenza A viruses: epidemiological study J Infect Chemother 2003; 9: 195-200.
137. Saito R, Sakai T, Sato I, Sano Y, Oshitani H, Sato M, Suzuki H. Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2. J Clin Microbiol 2003; 41: 2164-2165.
138. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swineorigin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615.
139. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009; 360: 2616-2625.
140. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005; 49: 556-559.
141. Laohpongspaisan C, Rungrotmongkol T, Intharathep P, et al. Why amantadine loses its function in influenza M2 mutants: MD simulations. J Chem Inf Model 2009; 49: 847-852.
142. Aldrich PE, Hermann EC, Meier WE, et al. Antiviral agents. 2. Structure-activity relationships of compounds related to 1 adamantanamine. J Med Chem 1971; 14: 535-543.
143. Kolocouris A, Tataridis D, Fytas G, et al. Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling. Bioorg Med Chem Lett 1999; 9: 3465-3470.
144. Zoidis G, Fytas C, Papanastasiou L, et al. Heterocyclic rimantadine analogues with antiviral activity. Bioorg Med Chem 2006; 14: 3341-3348.
145. Hu WH, Zeng SG, Li CF, Jie YL, Li ZY, Chen L. Identification of Hits as matrix-2 protein inhibitors through the focused screening of a small primary amine library. J Med Chem 2010; 53: 3831-3834.
146. Zoidis G, Kolocouris N, Naesens L, De Clercq E. Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity. Bioorg Med Chem 2009; 17: 1534-1541.
147. Zhao X, Li CF, Zeng SG, Hu WH. Discovery of highly potent agents against influenza A virus. Eur J Med Chem 2011; 46: 52-57.
148. Judd AK, Sanchez A, Bucher DJ, Huffman JH, Bailey K, Sidwell RW. In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob Agents Chemother 1997; 41: 687-692.
149. Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res 2000; 48: 1-16.
150. Wang J, Cady SD, Balannik V, Pinto LH, DeGrado WF, Hong M. Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc 2009; 131: 8066-8076.